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chemotherapy may be associated
with increased concentrations of
GAPDH mRNA. Because circulating
GAPDH mRNA in cancer patients
was thought to originate in apoptotic
cancer cells (2, 5), the increased con-
centrations of GAPDH mRNA de-
tected may be caused by apoptosis in
the placental residue in our case.
We conclude that real-time quanti-
tative RT-PCR is a sensitive method
to monitor changing mRNA concen-
trations resulting from apoptotic ef-
fects in the placenta and to evaluate
invading conditions of the tropho-
blastic villus.
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Clinical Relevance of Biological
Variation of B-Type Natriuretic
Peptide
To the Editor:
The cardiac natriuretic hormones
(CNHs), atrial (ANP) and B-type na-
triuretic peptide (BNP), are peptides
produced and secreted by the atrial
and ventricular cardiomyocytes, re-
spectively. ANP and BNP share po-
tent diuretic, natriuretic, and vascu-
lar smooth-muscle-relaxing effects
and interact with the hormonal and
nervous systems (1–3). Stimulation
by hemodynamic overload, as well
as by several neuroendocrine (in-
cluding -adrenergic agonists, angio-
tensin II, endothelins, and vasopres-
sin) and immunologic agents and by
growth factors, modulates the pro-
duction of CNHs by the human heart
(1, 2). CNHs and their respective
counter-regulatory neurohormonal
systems (including the adrenergic,
endothelin, and renin-angiotensin-
aldosterone systems) form a physio-
logic negative feedback mechanism
that regulates cardiac output by con-
trolling blood pressure and heart rate
as well as by fluid and electrolyte
homeostasis (1, 2).
The clinical relevance of measure-
ment of BNP and its related peptides
as diagnostic tools and prognostic
markers in patients with cardiovas-
cular diseases has been confirmed
recently (2, 3). To achieve correct in-
terpretation of serial test results that
are collected for follow-up or for
tailored treatment of heart failure pa-
tients, several studies (4–8) recently
evaluated the biological variation of
BNP and its related peptides in both
healthy persons and cardiac patients.
Because of secretory bursts and its
rapid turnover (half-life 15–20
min), it is not surprising that intrain-
dividual biological variations of
plasma BNP concentrations were
found to be very large in both
healthy persons and in patients with
heart failure (ranging from 30% to
50%) (4, 6, 8). Assuming a random
variation around a homeostatic set
point, the calculated reference
change values at 95% confidence
ranged from 99% to 130% for BNP in
healthy persons and patients (4, 6–
8). According to this estimated con-
fidence interval, only a decrease
50% or an increase greater than
twofold in plasma BNP should be
assumed to be statistically significant
in an individual patient.
In contrast to this assumption, a
recent clinical trial (9 ) has suggested
that a BNP decrease less than this
calculated reference change could be
clinically relevant in patients with
heart failure. In that study, only the
group of patients treated with the
beta-blocker agent carvedilol, who
responded on average with a de-
crease of only 38% in plasma BNP,
showed a clinical improvement (9 ).
Furthermore, several studies have
demonstrated that cardiovascular
risk (mortality or major cardiovascu-
lar events) increases continuously
and progressively throughout the
whole range of BNP concentrations
in patients with cardiovascular dis-
eases (i.e., an absolute threshold for
risk cannot be determined) (2 ).
To explain these conflicting find-
ings, it should be noted that BNP
secretion is closely regulated by spe-
cific pathophysiologic mechanisms.
Thus, changes in plasma hormone
concentrations cannot be interpreted
as random variations around a set
point, but as strictly determined by
the activation point of the counter-
regulatory system and by changes in
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hemodynamics. Clinicians should
look at intraindividual variations in
BNP as a mirror of variation in neu-
roendocrine network activity.
According to this hypothesis, we
suggest that all changes in BNP con-
centration should potentially be con-
sidered as clinically relevant, even
when they are narrower than the
calculated intraindividual biological
variation, because these variations
reflect changes in activation of the
neuroendocrine system as a result of
specific pathophysiologic mecha-
nisms. In other words, BNP varia-
tions should be interpreted and con-
sidered by physicians, in the same
manner as variations in heart rate
and blood pressure, by taking into
account clinical history and examina-
tion, including response to specific
treatments, as well as laboratory and
instrumental test findings.
There is another important practi-
cal consequence of this approach. At
an intraindividual biological varia-
tion of 30%, the estimated impreci-
sion goal for BNP immunoassays
should be 15% (i.e., equal to one half
of the intraindividual variation)
(10, 11). On the contrary, we suggest
that all measured variations of
plasma BNP 3 times the analytical
imprecision of the assay used (i.e., 3
SD of the assay variability) should
potentially be considered as clini-
cally relevant. According to this ap-
proach, the assay imprecision of BNP
immunoassays should be as low as
possible. A recent study from our
laboratory evaluated the analytical
imprecision of several commercial
BNP immunoassays (12 ). On aver-
age, this study demonstrated that
analytical performance, as well as
reference and decision values, varied
greatly among the BNP assay meth-
ods; in particular, the imprecision of
these immunoassays varied, on aver-
age, from 15% (the worst) to 5%
(the best) (12 ). Evidently, the immu-
noassay with the best imprecision is
able to detect significantly narrower
changes in BNP concentrations (i.e.,
variations of 15% for the method
with the lowest imprecision).
We suggest that only clinical crite-
ria should be used to evaluate the
pathophysiologic relevance of the
measured variation in BNP concen-
tration (defined as greater than 3 SD
of assay variability) in an individual
patient. Of course, the large number
of pathophysiologic mechanisms af-
fecting the CNH system may make it
difficult for clinicians to recognize
the cause(s) of variations in that sys-
tem’s activity. However, we believe
that BNP assays should be consid-
ered as an intellectual stimulus in the
search for explanations of the varia-
tions in hormone concentrations and
their relationship to pathophysio-
logic stimuli and/or pharmacologic
interventions. In this sense, assess-
ment of the time course of BNP con-
centrations may be a novel, meaning-
ful diagnostic tool for the follow-up
of patients with cardiac diseases.
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N-Terminal pro-B-Type Natriuretic
Peptide Concentrations in Mothers
just before Delivery, in Cord Blood,
and in Newborns
To the Editor:
The role of the heart as an endocrine
organ was established in 1981 by de
Bold et al. (1 ). Usually, in adults,
atrial natriuretic peptide (ANP) and
B-type natriuretic peptide (BNP) are
secreted mainly by the cardiac atria
and ventricles, respectively (2). Plas-
ma concentrations of these peptides,
particularly that of BNP, have been
shown to reflect cardiac dysfunction
and volume overload in adults and
children (3–8).
There is evidence that these pep-
tides have possible roles during fetal
life in the regulation of organogene-
sis of the heart and the cardiovascu-
lar system, in the regulation of blood
pressure and water balance in the
developing embryo, and in the tran-
sition from fetal to extra-uterine life
(9 ). BNP may also have an important
role in the regulation of amniotic
fluid volume (10 ).
Sparse data exist regarding N-ter-
minal proBNP (NT-proBNP) concen-
trations in umbilical cord blood and
in the newborn during the first days
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